Products

ASX
LCT 0.250   Last updated 11.18 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

DIABECELL®

DIABECELL® is a breakthrough cell therapy that has the potential to change the lives of the millions of people worldwide with type 1 diabetes.
 

Type 1 diabetes usually requires life-long treatment with regular insulin injections.
 

DIABECELL is an insulin-producing cell product derived from pigs for the treatment of type 1 diabetes. These islet cells are self-regulating and efficiently secrete insulin in the patient’s body.
 

The treatment involves introducing encapsulated pig cells into the patient’s abdomen in a simple laparoscopic procedure. Living Cell Technologies’ unique proprietary encapsulation technology prevents the islet cells from being attacked by the patient’s immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side effects.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.